Neuro-Bio
Neuro-Bio is a privately held, pre-clinical UK biopharmaceutical company developing the T14 14mer peptide platform for early Alzheimer's diagnostics, the NBP-14 therapeutic, and adjacent applications in oncology, dermatology, and diabetic retinopathy.
- Company typePrivate
- Founded2013
- HeadquartersAbingdon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Neuro-Bio does
Neuro-Bio Ltd is a privately held, pre-clinical stage British biopharmaceutical company incorporated in 2013 and headquartered at Culham Campus, Abingdon, Oxfordshire. The company is built on approximately four decades of neuroscience research conducted by its founder and CEO, Baroness Professor Susan Greenfield, at the University of Oxford, and operates on a novel hypothesis that a 14-amino-acid peptide called T14 is a primary driver of neurodegeneration in the adult brain, acting upstream of amyloid. Around this hypothesis Neuro-Bio has assembled a development platform covering diagnostics, therapeutics, and a proprietary non-transgenic animal model.
The company's lead therapeutic asset is NBP-14, a small-molecule/peptide variant targeting T14, currently in pre-clinical development toward IND status. Its diagnostic portfolio comprises an aptamer-based lateral flow test for the T14 biomarker in saliva and nasal secretions (developed with Aptamer Group's Optimer binders), intended to detect Alzheimer's disease up to 20 years before clinical symptoms, and a saliva immunodetection assay. Beyond Alzheimer's, Neuro-Bio is extending the same T14/NBP-14 mechanism into oncology (anti-metastatic action, in vivo testing via Xenopat), dermatology (skin aging applications), a rapamycin alternative acting on mTORC1, and diabetic retinopathy. The portfolio is supported by 22 registered patents and a sustained publication record in journals including Alzheimer's & Dementia.
Neuro-Bio has no commercial products and no recurring product revenue. The current business model is pre-commercial: the company raises equity from individual investors in tranches of £20,000 to £500,000 at pre-agreed valuations under HMRC-advanced-assured EIS relief, pursues academic and industry research collaborations (Oxford, Exeter, Edinburgh, Monash, Swansea, NeuRA, San Raffaele, LifeArc, Aptamer Group, Unilever, among others), and is positioning for future out-licensing of therapeutic and diagnostic assets to pharmaceutical partners. Go-to-market activity centers on enterprise field sales to investors and partners, supported by active participation in industry conferences (London Biotechnology Show, BioWales, Global Mind Brain Health Summit, Brain-Nose Symposium, events in Zurich, Barcelona, and Milan), scientific publications, LinkedIn outreach, and media coverage.
Neuro-Bio firmographics
Firmographics- Name
- Neuro-Bio
- Legal name
- Neuro-Bio Ltd
- Website
- https://neuro-bio.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neuro-Bio is a privately held, pre-clinical UK biopharmaceutical company developing the T14 14mer peptide platform for early Alzheimer's diagnostics, the NBP-14 therapeutic, and adjacent applications in oncology, dermatology, and diabetic retinopathy.
- Ownership category
- akta.pro rank
Neuro-Bio industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics and Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Neuro-Bio is headquartered
LocationHeadquarters
- HQ city
- Abingdon
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Neuro-Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapeutic Licensing/Royalties: Future revenue anticipated from licensing NBP-14 therapeutic compounds to pharmaceutical partners upon successful clinical development and regulatory approval. Currently in pre-clinical phase toward IND status.
- Diagnostic Product Licensing: Revenue potential from licensing diagnostic technology (lateral flow test and immunodetection tests) for T14 biomarker detection in nasal secretions and saliva.
- Pipeline Asset Development: Development of additional assets including oncology applications (anti-metastatic action), dermatology (skin aging), rapamycin alternatives, and diabetic retinopathy treatment with external partners.
- Investment Capital: Private company raising investment capital with individual investments ranging from £20,000 to £500,000 at pre-agreed valuations. EIS eligible with advanced assurance from HMRC.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Private Investment - Minimum £20,000 to Maximum £500,000 |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Neuro-Bio product offering
Product offeringCore offering
Neuro-Bio is a preclinical-stage biopharmaceutical company developing a first-in-class approach for diagnosing and treating Alzheimer's disease based on a novel T14 peptide mechanism that operates upstream of amyloid. Its portfolio comprises the lead therapeutic candidate NBP-14 (preclinical, toward IND), two diagnostic tests for pre-symptomatic Alzheimer's detection (a lateral flow test for T14 in nasal secretions via Aptamer Group collaboration, and a saliva-based immunodetection test), and a first-in-class non-transgenic animal model of Alzheimer's disease. Pipeline candidates also extend the platform to oncology (anti-metastasis), dermatology (skin aging), and diabetic retinopathy indications.
Product overview
Neuro-Bio is a pre-clinical stage biopharmaceutical company developing a first-in-class approach for diagnosing and treating Alzheimer's disease based on a novel biological mechanism involving the T14 peptide. The company's portfolio includes: (1) NBP-14, the lead therapeutic compound in preclinical development for Alzheimer's disease treatment; (2) two diagnostic products - a lateral flow test for T14 detection in nasal secretions using Aptamer's Optimer technology, and a clinical immunodetection test in saliva; (3) a proprietary non-transgenic animal model of Alzheimer's disease; and (4) multiple therapeutic pipeline candidates including treatments for oncology (metastasis), dermatology (skin aging), rapamycin-sensitive applications, and diabetic retinopathy. The company operates from Culham Campus, Oxfordshire, and was incorporated in 2013.
Differentiator
Problem solved
Functional benefit
Products and services
- NBP-14 Therapeutic Compound Lead therapeutic compound in preclinical phase for treating Alzheimer's disease by combatting the T14 toxin to stabilize cell loss. Targeting IND status as the company's core therapeutic candidate.
- T14 Lateral Flow Diagnostic Test (Nasal Secretions) Lateral flow antigen test for detecting the T14 peptide in nasal secretions using Aptamer Group's Optimer binders, designed to detect Alzheimer's disease up to 20 years before symptoms appear as a non-invasive early-detection diagnostic.
- T14 Saliva Immunodetection Diagnostic Clinical diagnostic test using immunodetection technology in saliva to detect the T14 peptide, providing diagnostic and prognostic potential for Alzheimer's disease.
- Non-Transgenic Alzheimer's Animal Model First-in-class authentic animal model of Alzheimer's disease developed in partnership with the University of Oxford, in which T14 peptide administration to normal rodents triggers the complete pathological scenario including impaired memory loss and traditional brain markers.
Quantifiable outcome
- Detecting Alzheimer's up to 20 years before symptoms appear through lateral flow test
- +1 more outcomes
Companies that use Neuro-Bio
Customer profileSegments3 records
Ideal customer profiles3 records
Neuro-Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature4 records
Neuro-Bio partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Aptamer GroupcoreCollaboration to develop a first-of-its-kind diagnostic lateral flow test using Neuro-Bio's unique T14 biomarker and Aptamer Group's Optimer binders for detecting Alzheimer's disease up to 20 years before symptoms appear.
- University of OxfordcoreNeuro-Bio originated from nearly 40 years of research at Oxford University by Baroness Greenfield. Ongoing collaboration includes non-transgenic animal model development and general research partnership. Note: Oxford does not own shares or have royalty arrangements with Neuro-Bio.
- University of ExetercoreCollaboration with Professor Lorna Harries' laboratory for RNA-based therapies research and accessing state-of-the-art equipment. Team members visit for experiments and project planning.
- San Raffaele HospitalminorBaroness Greenfield visited Milan for meetings with San Raffaele Hospital regarding prospective collaboration and investment discussions.
- UK Atomic Energy Authority (UKAEA)minorNeuro-Bio hosts events at Culham Campus alongside UKAEA. Innovation sessions held jointly with UKAEA Innovation team. Neuro-Bio's Office Manager attends campus community events.
- XenopatminorExternal partner currently testing NBP-14 in vivo for anti-metastatic oncology applications.
- LifeArcminorListed collaborator on Neuro-Bio's website for diagnostic development.
- NeuRAminorListed as collaborator on Neuro-Bio's website.
- Monash UniversityminorListed as collaborator on Neuro-Bio's website.
- Swansea UniversityminorListed as collaborator on Neuro-Bio's website. Student internships sourced from Swansea.
- University of EdinburghminorListed as collaborator on Neuro-Bio's website.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
Neuro-Bio competitors and assessment
Company assessmentEmerging players
- Quanterix: Commercial-stage diagnostics platform using ultra-sensitive biomarker detection (Simoa technology) for neurology applications including Alzheimer's. Adjacent to Neuro-Bio's biomarker diagnostic approach, though focused on blood-based assays rather than saliva.
- Cogstate: Digital cognitive assessment company providing tools for CNS clinical trials and early Alzheimer's detection. Partial overlap with Neuro-Bio's early-detection thesis, though focused on digital cognitive testing rather than biomarker detection.
- BioArctic: Swedish biotech developing antibodies and diagnostics for neurodegenerative diseases including Alzheimer's. Comparable platform approach to CNS protein targets with both therapeutic and diagnostic programs in development.
Direct peers
- Anavex Life Sciences: Clinical-stage biotech developing novel small-molecule therapeutics for Alzheimer's and other CNS diseases via a proprietary mechanism (sigma-1 receptor). Most directly comparable to Neuro-Bio given similar platform-based, non-amyloid CNS approach and small-cap pre-commercial profile.
- C2N Diagnostics: US-based diagnostics company developing blood-based biomarker tests for early Alzheimer's detection (PrecivityAD). Comparable to Neuro-Bio's Aptamer partnership for early AD detection, both targeting the pre-symptomatic diagnostic opportunity.
- AC Immune: Clinical-stage Swiss biotech developing both therapeutics and diagnostics for neurodegenerative diseases including Alzheimer's. Most comparable peer in terms of paired diagnostic + therapeutic strategy and CNS focus.
- Prothena Corporation: Clinical-stage biotech developing protein-targeted therapeutics for neurodegenerative diseases including Alzheimer's. Comparable in platform-based CNS pipeline, intellectual property depth, and partnership-driven development model.
- Cassava Sciences: Late-stage clinical biotech focused on Alzheimer's disease with a novel mechanism (simufilam) targeting an alternative pathway to amyloid. Comparable to Neuro-Bio in being a small-cap, mechanism-differentiated AD company, though Cassava is meaningfully further along clinically.
Broad incumbents
- Biogen: Large commercial-stage biopharma with leading Alzheimer's franchise (Leqembi partnership with Eisai). Represents the dominant incumbent whose amyloid-focused strategy defines the competitive context in which Neuro-Bio's T14 mechanism must differentiate.
- Eli Lilly: Global pharmaceutical leader with a major Alzheimer's franchise (Kisunla/donanemab) and extensive neurodegenerative disease pipeline. The benchmark large-cap player against which any novel AD mechanism like T14 must ultimately compete commercially.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Neuro-Bio social profiles
Digital presenceNeuro-Bio compliance and trust
Trust signalCompliance1 record
Neuro-Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neuro-Bio leadership team
Management profileNumber of profiles
Profiles13 records
Neuro-Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neuro-Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neuro-Bio
What does Neuro-Bio do?
Neuro-Bio is a preclinical-stage biopharmaceutical company developing a first-in-class approach for diagnosing and treating Alzheimer's disease based on a novel T14 peptide mechanism that operates upstream of amyloid. Its portfolio comprises the lead therapeutic candidate NBP-14 (preclinical, toward IND), two diagnostic tests for pre-symptomatic Alzheimer's detection (a lateral flow test for T14 in nasal secretions via Aptamer Group collaboration, and a saliva-based immunodetection test), and a first-in-class non-transgenic animal model of Alzheimer's disease. Pipeline candidates also extend the platform to oncology (anti-metastasis), dermatology (skin aging), and diabetic retinopathy indications.
Is Neuro-Bio a public or private company?
Neuro-Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neuro-Bio founded?
Neuro-Bio was founded in 2013. It employs 11 to 50 people.
Where is Neuro-Bio based?
Neuro-Bio is headquartered in Abingdon, United Kingdom, in the Europe region.
How does Neuro-Bio make money?
Four revenue lines are on record. Therapeutic Licensing/Royalties are the primary driver. The others are diagnostic Product Licensing, pipeline Asset Development and investment Capital.
Who are Neuro-Bio's main competitors?
Emerging players on record are Quanterix, Cogstate and BioArctic. Direct peers are Anavex Life Sciences, C2N Diagnostics, AC Immune, Prothena Corporation and Cassava Sciences. Broad incumbents are Biogen and Eli Lilly.
Does Neuro-Bio have an API?
No public API is recorded for Neuro-Bio.
What industry is Neuro-Bio in?
Neuro-Bio's product category is Neurodegenerative Disease Therapeutics and Diagnostics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2834.